PAREXEL HEMATOLOGY/ONCOLOGY EXPERTS TO ADDRESS SUCCESSFUL DEVELOPMENT OF NOVEL CANCER TREATMENTS AT ASCO ANNUAL MEETING
Boston, MA, June 3, 2010 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that leading hematology and oncology experts from the Company will be available during the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4 – 8, 2010 in Chicago, Illinois, to address the successful development of novel cancer treatments.
During the ASCO meeting, attendees can visit PAREXEL’s Booth #22107 in the exhibit hall to meet with experts from PAREXEL’s global Hematology/Oncology Team who will discuss how new anticancer agents will be positioned in the treatment of patients, from the earliest phases of clinical development through the approval process and into post-marketing. These experts will discuss their experience and expertise in helping biopharmaceutical companies advance important innovations through an understanding of unmet medical needs and standards of available cancer care worldwide.
Experts from Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL, will also be available to discuss advanced capabilities for imaging-based oncology and hematology clinical trials. Representatives from Perceptive will highlight the benefits of combining the expertise of its global medical imaging team with PAREXEL’s clinical and therapeutic area expertise to help clients make better, more informed decisions regarding the best use of medical imaging and associated clinical data in their development programs. Additionally, Perceptive experts will address the incorporation of RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria into Independent Review Charters for regulatory approval of oncology treatments.
PAREXEL has experience across a broad range of cancer indications as well as all classes of therapeutics including cytotoxics, biologics, targeted therapies, immunotherapies, vaccine therapies, and supportive treatments, such as blood products, growth factors, antiemetics, and analgesics. PAREXEL’s Hematology/Oncology Team offers expertise to help clients with every facet of drug development, including protocol review, safety assessment, clinical development, medical imaging, technology integration, regulatory affairs, and product lifecycle management. Comprehensive services provided by the team include the planning, design, and management of feasibility studies, Phase I – IV trials, and post-marketing studies as well as site selection, patient recruitment, data analysis, non-clinical evaluation, and IND/NDA submissions. PAREXEL leverages the experience and relationships that its experts have with leading cancer centers and key opinion leaders in its ongoing collaborative efforts.
PAREXEL applies a proven, therapeutically focused expertise methodology to clinical development programs across a broad range of areas. For more information about PAREXEL’s in-depth expertise in the oncology, neurology, cardiology, and infectious disease therapeutic areas, as well as a broad range of other therapeutic areas, visit http://www.PAREXEL.com/therapies/.
Information about the ASCO Annual Meeting can be found at: http://chicago2010.asco.org/Home.aspx.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.